Categories Earnings, Health Care

Merck & Co. (MRK) Q4 earnings beat estimates, revenue slightly misses

Merck & Co., Inc. (NYSE: MRK) reported stronger than expected earnings for the fourth quarter of 2019. However, the company’s sales slightly missed the forecast. The stock declined early Wednesday immediately after the announcement.

Worldwide sales of the drugmaker rose 8% year-over-year to $11.87 billion but fell short of expectations. Excluding foreign exchange impacts, sales grew 9%. The top-line benefitted from the strength of oncology and human health vaccines.

Merck & Co. (MRK) Q4 earnings beat estimates, revenue slightly misses

Net earnings, on an adjusted basis, rose to $1.16 per share from $1.04 per share in the fourth quarter of 2018 and exceeded the market’s forecast.
Unadjusted net income advanced to $2.36 billion or $0.92 per share from $1.83 billion or $0.69 per share last year.

Also see: Vertex Pharmaceuticals Q4 2019 Earnings Snapshot

“As evidenced by our results and our 2020 guidance, Merck had an extraordinary year and is in a position of operational and financial strength. It is this position of strength, born of our focused execution, that gives us the confidence to spin off our Women’s Health, trusted Legacy Brands and Biosimilar products into a new company,” said CEO Kenneth Frazier.


Looking ahead, the company expects worldwide sales to be between $48.8 billion and $50.3 billion in fiscal 2020, which includes a negative impact of about 1% from foreign exchange. Full-year unadjusted earnings are expected to be in the range of $4.57 per share to $4.72 per share. The management is looking for adjusted earnings per share of $5.62-$5.77 for the year.


Merck said it is considering a spin-off of its Women’s Health business, trusted legacy brands, and biosimilar products into a new company so as to focus on the “key growth pillars.”

Also Read:  Thermo Fisher Scientific Inc (TMO) Q3 2020 Earnings Call Transcript

During the quarter, the company’s cancer drug KEYTRUDA obtained FDA approval for use as monotherapy for the treatment of patients with high-risk, non-muscle invasive bladder cancer.


As part of diversifying its oncology portfolio, the company closed the acquisition of ArQule last month. It also entered into a tie-up with Taiho Pharmaceutical and Astex Pharmaceuticals focused on the development of small-molecule inhibitors against several drug targets.

Related: Merck Q3 2019 Earnings Conference Call Transcript

Merck’s shares dropped during Wednesday’s premarket session, soon after the earnings announcement. The stock had closed the last session higher.

Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text

Most Popular

Earnings calendar for the week of Oct. 26

Bringing fresh optimism to the virus-hit market, U.S jobless claims for the week ended October 17 slipped to the lowest level since the onset of the pandemic, in a sign

Southwest Airlines (LUV) expects business travel to remain down well into next year

Shares of Southwest Airlines Co. (NYSE: LUV) were up over 2% in afternoon hours on Friday. The stock has gained 35% over the past three months. The company reported better-than-expected

Big banks have their eyes on second half of 2021

The biggest stimulus package of all time, which was meant to boost consumption has actually led to more deposits, inflating the size of banks’ balance sheets. A working paper shows

3 thoughts on “Merck & Co. (MRK) Q4 earnings beat estimates, revenue slightly misses

Comments are closed.